Last Updated on December 21, 2024 by The Health Master
EIR
Alembic Pharma, a leading Indian pharmaceutical company, has achieved a significant milestone with the receipt of a clean Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA).
This positive outcome follows a thorough inspection of the company’s Oral Solid Formulation Facility (F-I) located in Panelav.
USFDA Inspection a Success:
The inspection, conducted from July 17th to 26th, 2024, was a rigorous assessment of the facility’s compliance with USFDA standards.
Alembic Pharma is pleased to announce that the inspection was completed without any Form 483 observations, indicating a successful outcome and adherence to regulatory requirements.
Alembic Pharma’s Commitment to Quality:
Alembic Pharma, a vertically integrated research and development company, is dedicated to providing high-quality generic pharmaceutical products to patients worldwide.
The company’s state-of-the-art manufacturing facilities are subject to stringent quality control measures and are approved by regulatory authorities in numerous countries, including the USFDA.
In conclusion, the receipt of a clean EIR from the USFDA is a testament to Alembic Pharma’s commitment to excellence in manufacturing and quality control.
This achievement reinforces the company’s position as a trusted supplier of generic pharmaceuticals and strengthens its global presence.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued Form 483 with observation to Torrent Pharma, Pithampur plant
USFDA Inspection successfully completed at Indian firm Laurus Labs
USFDA inspection finds these lapses at Zydus Lifesciences
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Over 340 Pharma Companies overdue for USFDA inspection in India and China
USFDA approval granted for Paliperidone extended-release Tablets
Telangana DCA crack down on unlicensed Medical Stores
Streamlining Drug Licensing: Online Portal Set to Revolutionize Processes
New Rules in India: Mandatory Registration under NDCTR, 2019
USFDA issued Form 483 with observation to Torrent Pharma, Pithampur plant
CDSCO approval granted for Durvalumab therapy with specified indication
DCC recommends amendment of Rules to curbing Antimicrobial Resistance
Drug alert: 59 drug samples declared as NSQ in August 2024
PvPI and Adverse Drug Reaction: A Crucial Component of Pharmacy Education: Dr. B Suresh
DCC recommends closely monitoring quality of Eye Drops
